Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDGK83)

Drug Name

NN1841 Drug Info

Synonyms

NovoThirteen (TN)

Indication

Disease Entry	ICD 11	Status	REF
Hemophilia	3B10.0	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Coagulation factor XIII (F13B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NN8717	DM1PI9G	Graft-versus-host disease	4B24	Phase 3	[3]
Tridegin	DMUHBSI	Thrombosis	DB61-GB90	Terminated	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT01253811) Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency. U.S.National Institutes of Health.
2	Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency. J Blood Med. 2014 Jul 9;5:107-13.
3	Topical recombinant thrombin at a concentration of 1000 IU/mL reliably shortens in vivo TTH and delivers durable hemostasis in the presence of heparin anticoagulation and clopidogrel platelet inhibition in a rabbit model of vascular bleeding. Ann Surg Innov Res. 2009; 3: 14.
4	Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii. Biochem J. 1997 Jun 15;324 ( Pt 3):797-805.